Biogen Inc, founded in 1978 and headquartered in Cambridge, Massachusetts, is a global biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases. The company's main focus includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease, positioning it as a leader in the biopharmaceutical industry.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| BIIB 3.25% 2051-02-15 USDBiogen Inc | United States | 2051-02-15 | 3.250 | 5.85 |
| BIIB 3.25% 2051-02-15 USDBiogen Inc | United States | 2051-02-15 | 3.250 | 5.85 |
| BIIB 4.05% 2025-09-15 USDBiogen Inc | United States | 2025-09-15 | 4.050 | 4.24 |
| BIIB 5.05% 2031-01-15 USDBiogen Inc | United States | 2031-01-15 | 5.050 | 4.32 |
| BIIB 5.20% 2045-09-15 USDBiogen Inc | United States | 2045-09-15 | 5.200 | 5.79 |
| BIIB 5.20% 2051-02-15 USDBiogen Inc | United States | 2051-02-15 | 5.200 | 5.85 |
| BIIB 5.75% 2035-05-15 USDBiogen Inc | United States | 2035-05-15 | 5.750 | 5.00 |
| BIIB 6.45% 2055-05-15 USDBiogen Inc | United States | 2055-05-15 | 6.450 | 6.00 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Biogen began issuing bonds in 2005 to support its growth initiatives and research funding. One notable issuance was a $1 billion bond in 2019, which aimed to finance a share buyback program and general corporate purposes. Biogen's current bond yields are competitive within the industry, reflecting a strong credit rating and investor confidence. Recently, the company introduced a 10-year senior unsecured note, showcasing its commitment to maintaining a robust capital structure in an evolving market landscape.